FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| Cytarabine | Acute Myeloid Leukemia | PHASE3 | ACTIVE_NOT_RECRUITING |
| Decitabine | Acute Myeloid Leukemia | PHASE3 | ACTIVE_NOT_RECRUITING |
| GM-CSF | Acute Myeloid Leukemia | PHASE3 | ACTIVE_NOT_RECRUITING |
| Galinpepimut-S + Montanide + GM-CSF | Malignant Pleural Mesothelioma | PHASE2 | COMPLETED |
| Herceptin | Breast Cancer | PHASE2 | COMPLETED |
| Montanide + GM-CSF | Malignant Pleural Mesothelioma | PHASE2 | COMPLETED |
| NeuVax vaccine | Breast Cancer | PHASE2 | COMPLETED |
| Trastuzumab | Breast Cancer | PHASE2 | COMPLETED |
| Azacitidine | Hematologic Malignancies | PHASE1 | RECRUITING |
| bortezomib | Multiple Myeloma | PHASE1 | COMPLETED |
SLS holds $107.1M in cash and burns about $6.9M/quarter from operations, giving an estimated runway of 46.7 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for SLS free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-01-09 | VAN NOSTRAND ROBERT L |
Purchase | $0 |
| 2026-01-09 | SCHEINBERG DAVID A |
Purchase | $0 |
| 2026-01-09 | Wasman Jane |
Purchase | $0 |
| 2026-01-09 | Kalin Katherine Bach |
Purchase | $0 |
| 2026-01-09 | Burns John Thomas |
Purchase | $0 |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for SLS and 2 more tickers of your choice.
Create Free Account →